Wilson Sonsini Goodrich & Rosati advised vTv Therapeutics on patent matters related to the transaction. vTv Therapeutics, a clinical-stage biopharmaceutical company, announced the closing of a private...
vTv Therapeutics’ $51 Million Private Placement Financing
Janux Therapeutics’ $296.5 Million Common Stock Offering
Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
Avidity Biosciences’ $400 Million Shares Private Placement
Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction. Avidity Biosciences, Inc. (Nasdaq: RNA) announced that it has agreed to sell 15,224,773...
Tenaya Therapeutics’ $50 Common Stock Offering
Wilson Sonsini Goodrich & Rosati advised Tenaya Therapeutics on the transaction, and Davis Polk & Wardwell advised the underwriters. Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage...
JIXING’s Collaborations with TMS
Wilson Sonsini Goodrich & Rosati advised Ji Xing Pharmaceuticals Limited (JIXING) on the transaction. TMS Co., Ltd. (TMS) and Ji Xing Pharmaceuticals Limited (JIXING) announced that...
Insilico Medicine’s License Agreement with Menarini Group
Wilson Sonsini Goodrich & Rosati represented Insilico in the transaction. Stemline Therapeutics, Inc. (Stemline), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology...
Bristol Myers Squibb’s $4.1 Billion Acquisition of RayzeBio
Covington advised Bristol Myers Squibb on the transaction, while Cooley and Wilson Sonsini Goodrich & Rosati advised RayzeBio Inc. Goodwin advised Centerview Partners in its role...
Radionetics Oncology’s $52.5 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Radionetics Oncology on IP matters related to the transaction. Radionetics Oncology announced that it has raised $52.5 million in Series...
Sudo Biosciences’s $116 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Sudo on intellectual property matters related to the transaction. Sudo Biosciences (“Sudo”) announced the close of a $116 million Series B...
Melinta Therapeutics’ Licensing Agreement with Venatorx Pharmaceuticals
Wilson Sonsini Goodrich & Rosati advised Venatorx on IP matters in the transaction. Melinta Therapeutics LLC (Melinta) and Venatorx Pharmaceuticals, Inc. (Venatorx), announced that they have...
LENZ Therapeutics’ Merger with Graphite Bio
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
Insilico Medicine’s $80 Million Agreement with Exelixis
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Exelixis, Inc. and Insilico Medicine announced that they have entered into an exclusive license agreement granting Exelixis...